Caplin Point Lab Reports Record High Sales and Profits in Q1 FY25
Caplin Point Laboratories, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company has received a ‘Buy’ call from MarketsMOJO, indicating positive growth potential.
According to the financial report, Caplin Point Lab has shown a positive performance in the quarter, with a score of 9 out of 11. This is a significant improvement from the previous quarter, where the score was 11. The company’s net sales for the quarter were at a record high of Rs 458.96 crore, with a consistent growth trend over the last five quarters. This indicates a strong and stable sales performance in the near future.
The operating profit (PBDIT) for the quarter was also at its highest at Rs 151.81 crore, with a consistent growth trend over the last five quarters. This shows a positive trend in the company’s operational efficiency and profitability. The profit before tax (PBT) less other income was also at its highest at Rs 135.82 crore, with a consistent growth trend over the last five quarters. This indicates a strong and stable financial performance for the company.
The profit after tax (PAT) for the quarter was also at its highest at Rs 123.97 crore, with a consistent growth trend over the last five quarters. This shows a positive trend in the company’s overall profitability. The earnings per share (EPS) for the quarter were at its highest at Rs 16.31, indicating an increase in profitability and higher earnings for shareholders.
However, the company’s debtors turnover ratio for the half-yearly period was at its lowest at 3.12 times in the last five half-yearly periods. This indicates a slower pace in settling the company’s debtors. Despite this, Caplin Point Lab has shown a strong and positive financial performance in the quarter ending March 2024.
Overall, Caplin Point Laboratories has shown a positive and stable financial performance in the quarter ending March 2024. With a ‘Buy’ call from MarketsMOJO, the company has a promising future in the pharmaceutical industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
{{text.big_txt}}
{{text .small_txt}}
{{dashverdictresult.dashboard.stock_details.short_name}}
SEND BY EMAIL
Register now to see if the stock’s characteristics match your investment style
Subscribe now to see if the stock's characteristics match your investment style
{{dashverdictresult.dashboard.risk_return_voltality.risk_type}}, {{dashverdictresult.dashboard.risk_return_voltality.return_type}}
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
| {{ value[0] }} | {{ value[1] }} | {{ value[2] }} | {{ value[3] }} |
Create your portfolio and know how much should this stock be in your portfolio
Subscribe now to know how much you should hold in this stock
We have found 2 better stocks that you can consider
{{dashverdictresult.dashboard.return_text}}
Investors Returns (3 years) –
| Period | 6M | 1Y | 2Y | 3Y |
| {{ keyd.val }} | ||||
| {{ keyd.val }} |
Quality: {{dashverdictresult.dashboard.dotsummary.q_txt}}
Valuation: {{dashverdictresult.dashboard.dotsummary.v_txt}}
Quarterly Financial Trend: {{dashverdictresult.dashboard.dotsummary.f_txt}}
Technicals: {{dashverdictresult.dashboard.dotsummary.tech_txt}}
Stock Info:
BSE – {{dashverdictresult.dashboard.stock_details.scripcode}}/ NSE – {{dashverdictresult.dashboard.stock_details.symbol}}
Market Cap – {{dashverdictresult.dashboard.priceinfo.mcap_class}} (Rs. {{dashverdictresult.dashboard.priceinfo.mcap| number :0}} cr)
Sector – {{dashverdictresult.dashboard.stock_details.ind_name}}
52 w H/L (Rs.) – {{dashverdictresult.dashboard.priceinfo.wk_high52}}/{{dashverdictresult.dashboard.priceinfo.wk_low52}}
Average vol (6M) – {{dashverdictresult.dashboard.priceinfo.vol}}
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
